These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Overview: Global and Local Impact of Antibiotic Resistance. Watkins RR; Bonomo RA Infect Dis Clin North Am; 2016 Jun; 30(2):313-322. PubMed ID: 27208761 [TBL] [Abstract][Full Text] [Related]
24. Antibiotic Resistance: The Need For a Global Strategy. Elder DP; Kuentz M; Holm R J Pharm Sci; 2016 Aug; 105(8):2278-87. PubMed ID: 27397433 [TBL] [Abstract][Full Text] [Related]
26. Development of new antibacterials: a laudable aim, but what is the value? Tillotson GS Clin Infect Dis; 2010 Sep; 51(6):752-3; author reply 754-5. PubMed ID: 20731567 [No Abstract] [Full Text] [Related]
30. Report reveals scope of US antibiotic resistance threat. Hampton T JAMA; 2013 Oct; 310(16):1661-3. PubMed ID: 24150445 [No Abstract] [Full Text] [Related]
31. Emerging antimicrobial resistance and newer tools to address the resistance. Goyal PK; Semwal A; Prakash A; Medhi B Indian J Pharmacol; 2019; 51(5):291-295. PubMed ID: 31831917 [No Abstract] [Full Text] [Related]
32. Management of Neonates Born at ≥35 0/7 Weeks' Gestation With Suspected or Proven Early-Onset Bacterial Sepsis. Puopolo KM; Benitz WE; Zaoutis TE; ; Pediatrics; 2018 Dec; 142(6):. PubMed ID: 30455342 [TBL] [Abstract][Full Text] [Related]
33. Neonatal bloodstream infections in a Ghanaian Tertiary Hospital: Are the current antibiotic recommendations adequate? Labi AK; Obeng-Nkrumah N; Bjerrum S; Enweronu-Laryea C; Newman MJ BMC Infect Dis; 2016 Oct; 16(1):598. PubMed ID: 27776490 [TBL] [Abstract][Full Text] [Related]
34. The Ethics of Antibiotic Resistance: Towards an Agenda for Feasible and Justified Global Health Policy. Munthe C; Nijsingh N; de Fine Licht K; Larsson DGJ Bioethics; 2019 Sep; 33(7):731-733. PubMed ID: 31423606 [No Abstract] [Full Text] [Related]
35. Questions about the 10 x '20 Initiative. Outterson K; Powers JH; Gould IM; Kesselheim AS Clin Infect Dis; 2010 Sep; 51(6):751-2; author reply 754-5. PubMed ID: 20731566 [No Abstract] [Full Text] [Related]
36. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. Kostyanev T; Bonten MJ; O'Brien S; Steel H; Ross S; François B; Tacconelli E; Winterhalter M; Stavenger RA; Karlén A; Harbarth S; Hackett J; Jafri HS; Vuong C; MacGowan A; Witschi A; Angyalosi G; Elborn JS; deWinter R; Goossens H J Antimicrob Chemother; 2016 Feb; 71(2):290-5. PubMed ID: 26568581 [TBL] [Abstract][Full Text] [Related]
37. Letter in response to the Infectious Diseases Society of America's 10 x '20 Initiative. Burgess DS; Slain D; Mohr J; Wong-Beringer A; Destache C; Suda K Clin Infect Dis; 2010 Sep; 51(6):753; author reply 754-5. PubMed ID: 20731568 [No Abstract] [Full Text] [Related]
38. Short summary of Swedres 2005, a report on Swedish antibiotic utilisation and resistance. Cars O; Olsson-Liljequist B; Lundh K Euro Surveill; 2007 Mar; 12(3):225. PubMed ID: 17439810 [TBL] [Abstract][Full Text] [Related]